Want to see CTEV full AI Analyst Report?
Top Page
Claritev
(NYSE:CTEV)
Select Model
Select Model
Rating:54Neutral
Price Target:
$26.00
▼(-33.99% Downside)
Action:Reiterated
Date:09/15/26
The score is held back primarily by weak financial quality (large net losses) and high balance-sheet risk (heavy debt and negative equity). Offsetting factors include a constructive earnings call with raised guidance and strong bookings/pipeline momentum, plus a mildly supportive technical backdrop. Valuation is also pressured by the negative P/E tied to ongoing losses.
Positive Factors
Raised financial guidance
Management’s higher full-year revenue and adjusted EBITDA outlook indicates confidence in the operating trajectory, while the increased cash-flow target supports improving execution. Sustaining these targets would strengthen earnings capacity and provide more resources for investment over the next several quarters.
Negative Factors
High leverage and negative equity
Heavy debt combined with negative equity materially limits financial flexibility and leaves the company less able to absorb operating shocks. Leverage can also constrain investment and capital allocation, making balance-sheet repair an important requirement for durable improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Raised financial guidance
Management’s higher full-year revenue and adjusted EBITDA outlook indicates confidence in the operating trajectory, while the increased cash-flow target supports improving execution. Sustaining these targets would strengthen earnings capacity and provide more resources for investment over the next several quarters.
Read all positive factors
Claritev (CTEV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$499.10M
Dividend YieldN/A
Average Volume (3M)130.97K
Price to Earnings (P/E)―
Beta (1Y)2.75
Revenue Growth6.32%
EPS Growth58.48%
CountryUS
Employees3,000
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-17.01
Shares Outstanding16,947,462
10 Day Avg. Volume155,233
30 Day Avg. Volume130,973
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-4.04
Price to Sales (P/S)0.73
P/FCF Ratio-57.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$45.83Price Target Upside16.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-15.12
Revenue Forecast (FY)$1.01B
Claritev Business Overview & Revenue Model
Company Description
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United Stat...
Claritev Earnings Call Summary
Earnings Call Date:Aug 07, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and financial momentum: multi-quarter revenue growth, record/near-record EBITDA and cash flow, significant bookings acceleration and a substantially enlarged pipeline. Management raised revenue and EBITDA guidance and highlighted successful execution across TPA, Claims Intelligence and AI-enabled initiatives. Offsetting considerations include timing and mix-driven pressure on revenue per claim, network comparables impacted by prior-year one-time items, a near-term Payments timing miss, and some volume/regulatory uncertainty that introduces short-term variability. Overall, the positive metrics and trajectory substantially outweigh the manageable timing and mix headwinds.Positive Updates
Revenue Growth and Record Quarter
Total revenue $257.5M in Q2, up 6.6% year-over-year — fifth straight quarter of YoY growth and the highest revenue quarter in 15 quarters (since Q3 2022).
Negative Updates
Network Revenue Impacted by Prior-Year One-Time Items
Network revenue would have been positive YoY excluding a prior-year one-time amount (Q2 last year $5.4M referenced; company also cited ~$18.5M of one-time revenue affecting full-year comparables). Management expects network to be down high single digits on a full-year comparable basis due to these prior-year items.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Record Quarter
Total revenue $257.5M in Q2, up 6.6% year-over-year — fifth straight quarter of YoY growth and the highest revenue quarter in 15 quarters (since Q3 2022).
Read all positive updates
Company Guidance
Claritev raised its full‑year revenue guidance to $1.00–$1.02 billion (4%–6% growth, a two‑percentage‑point increase) and asked investors to model Q3 revenue flat with Q2, raised full‑year adjusted EBITDA guidance to $610–$620 million (≈61% margin), left capital spending unchanged at $160–$170 million, and increased free cash flow guidance by $5 million to $5–$15 million; management expects adjusted cash conversion to normalize to >50% by year‑end, reiterated that new ACV bookings typically convert to first revenue in ~2–4 quarters and fully annualize after another ~4 quarters, reaffirmed a target of at least 50% ACV bookings growth for 2026 (Q2 ACV was $30M, H1 ACV ~$74M with a $100M full‑year stretch goal), highlighted a >$300M active pipeline with >3x coverage, and reminded listeners of the near‑term cash seasonality (Q1 and Q3 generally consume cash; Q2–Q4 generate cash).Claritev Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
18
Very Negative
Cash Flow
44
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 994.67M | 965.41M | 930.62M | 961.52M | 1.08B | 1.12B |
| Gross Profit | 440.33M | 266.58M | 691.22M | 726.06M | 875.62M | 942.31M |
| EBITDA | 590.59M | 475.44M | -1.01B | 651.93M | 158.32M | 814.99M |
| Net Income | -283.11M | -284.28M | -1.65B | -91.70M | -572.91M | 102.08M |
Balance Sheet | ||||||
| Total Assets | 4.76B | 4.89B | 5.15B | 6.96B | 7.37B | 8.22B |
| Cash, Cash Equivalents and Short-Term Investments | 14.37M | 16.81M | 16.85M | 71.55M | 334.05M | 185.33M |
| Total Debt | 4.62B | 4.63B | 4.54B | 4.57B | 4.78B | 4.93B |
| Total Liabilities | 5.05B | 5.06B | 5.07B | 5.26B | 5.58B | 5.88B |
| Stockholders Equity | -294.56M | -173.90M | 84.02M | 1.71B | 1.79B | 2.34B |
Cash Flow | ||||||
| Free Cash Flow | -17.92M | -12.28M | -10.51M | 62.87M | 282.63M | 320.10M |
| Operating Cash Flow | 133.03M | 117.32M | 107.62M | 171.72M | 372.36M | 404.69M |
| Investing Cash Flow | -142.38M | -121.02M | -118.12M | -249.79M | -104.45M | -228.38M |
| Financing Cash Flow | -30.27M | 2.36M | -41.31M | -180.99M | -115.74M | -114.68M |
Claritev Technical Analysis
Negative
39.39
Price Trends
32.40
Negative
30.03
Negative
27.48
Negative
Market Momentum
-1.41
Positive
26.81
Positive
8.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTEV, the sentiment is Negative. The current price of 39.39 is above the 20-day moving average (MA) of 35.68, above the 50-day MA of 32.40, and above the 200-day MA of 27.48, indicating a bearish trend. The MACD of -1.41 indicates Positive momentum. The RSI at 26.81 is Positive, neither overbought nor oversold. The STOCH value of 8.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTEV.
Claritev Risk Analysis
Claritev disclosed 62 risk factors in its most recent earnings report. Claritev reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Claritev Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $4.91B | 34.39 | 3.59% | ― | 19.23% | 44.44% | |
68 Neutral | $91.36M | 29.51 | 16.56% | ― | 15.07% | ― | |
66 Neutral | $626.92M | 56.21 | 3.01% | ― | 12.93% | ― | |
54 Neutral | $499.10M | -1.47 | 139.56% | ― | 6.32% | 58.48% | |
53 Neutral | $142.23M | -0.47 | -129.70% | ― | -7.54% | -143.41% | |
52 Neutral | $429.63M | -0.81 | -99.16% | ― | -4.50% | -184.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CTEV
Claritev
25.04
-24.81
-49.77%
CCLD
CareCloud
2.06
-1.27
-38.14%
EVH
Evolent Health
3.62
-5.30
-59.42%
PHR
Phreesia
9.68
-13.77
-58.72%
HCAT
Health Catalyst
1.72
-1.09
-38.79%
WAY
Waystar Holding Corp.
24.76
-12.33
-33.24%
Claritev Corporate Events
Business Operations and StrategyExecutive/Board Changes
Claritev Adds AI Expert Ben Letham to Board
Positive
Sep 15, 2026
On September 14, 2026, Claritev Corporation appointed AI expert Ben Letham to its Board of Directors as a Class I director and member of the Risk Committee, filling the vacancy created by the passing of director John Prince. Letham will serve as a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.